Currently, the growing aging population is leading to an unprecedented rise in older Americans. The number of Americans aged 65 years and older is projected to double by 2060, contributing to an increase in the prevalence of age-related diseases, including Alzheimer’s disease (AD) and related dementias (ADRD). Today, an estimated 5.8 million Americans are living with AD. By 2050, that number is projected to surge to 14 million.
Accounting for up to 80% of all dementia cases, Alzheimer’s disease (AD) currently affects over 50 million people across the globe. With 10 million new cases of dementia diagnosed each year, this number is expected to increase with a steadily rising aging population leading experts to forecast there will be nearly 152 million dementia patients by the year 2050. The significant caregiving and economic burden of this condition necessitate innovations in therapeutics that will enable clinicians to implement effective prevention and treatment methods. Today, the socio-economical cost of dementia is estimated at $1 trillion – and this is expected to double by the end of the decade if rates do not slow down.
As the world continues to grapple with the COVID-19 pandemic, the importance of regenerative medicine, and its many facets ranging from vaccine development to novel therapeutics, is being highlighted. While the industry has been receiving increased attention from investment firms in recent years, the recent boost in financial support from governments across the globe as part of the novel coronavirus response is expected to further propel the market. Businesses based on regenerative medicine are experiencing a flood of cash and record valuations – all factors predicted to fuel the market surge in coming years.